Bevacizumab is a humanized anti-VEGF monoclonal IgG1 antibody (molecular weight, 149 kDa) that selectively binds to and neutralizes VEGF, thereby preventing it from binding to its cell surface VEGFRs, leading to reduced MVD in tumors, thus limiting the blood supply to tumor tissues and lowering interstitial tissue pressure and vascular permeability [25]. The gene discussed is VEGFA; the disease is neoplasm.